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132 Poster Session IIIL-2/GM-CSF except for mild flu-like symptoms. The table below
summarizes quantitative analysis of immune activation. Values rep-
resent means1/- standard error at day 0 (first day of GM-CSF), day
8 (prior to start of IL-2) and day 14 (last day of IL-2 and GM-CSF).
P-values are based on paired t-test analysis of day 8 versus day 0 and
day 14 versus day 0, respectively. Flow cytometric analysis showed
an increase in the numbers of T-lymphocytes (CD3) andT-cell sub-
sets (CD3/CD8 and CD3/CD4) as well as an increase in natural
killer cells (CD16/56). Although no differences were seen in the
number of dendritic cell subsets, DC1/DC2 ratios decreased with
the administration of GM-CSF/IL-2. Limited (n 5 4) CD4/
FoxP3 analysis did not show change in absolute numbers with
administration of GM-CSF/IL-2 (data not shown). In conclusion,
cytokine therapy with IL-2/GM-CSF is well tolerated and is an
alternative to DLI for relapse after ASCT. Flow cytometry analysis
demonstrated a quantitative increase in immune effector cells and
polarization to DC2.Flow Cytometry of Immune Effector Cells
D0 D8 D14 P-Value P-Value(Mean ± SE) (Mean ± SE) (Mean ± SE) (Day 8–0) (Day 14–0)CD3 (K/uL) 309 ± 117 535 ± 103 1306 ± 403 0.034 0.027CD3/CD8 (K/uL) 94 ± 42 174 ± 33 325 ± 90 0.021 0.029CD3/CD4 (K/uL) 309 ± 117 404 ± 102 977 ± 310 0.249 0.045CD16/CD56 (K/uL) 124 ± 60 404 ± 110 496 ± 162 0.029 0.044CD19 (K/uL) 68 ± 39 89 ± 36 116 ± 31 0.183 0.044Tot. Lymphs (K/uL) 488 ± 167 942 ± 160 2353 ± 532 0.016 0.013CD11(DC1) (K/uL) 97 ± 60 46 ± 32 33 ± 27 0.108 0.101CD123(DC2) (K/uL) 32 ± 7 40 ± 16 45 ± 36 0.694 0.628DC1/DC2 2.77 ± 1.26 0.68 ± 0.35 0.61 ± 0.07SE 5 Standard Error; DC5 dendritic cells.360
WHERE TO BIOPSY IN THE GASTROINTESTINAL (GI) TRACT TO DIAG-
NOSE ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) IN PEDIATRIC
ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS (AlloSCT)
Martinez, M., Billote, G., Desai, M., Chu, K., Remotti, H., Satwani, P.,
Cairo, M.S., DeFelice, A. Columbia University, New York, NY.
Background & Aims: Despite therapeutic advances, GI
AGVHD continues to be a serious threat after alloSCT contribut-
ing to significant morbidity and mortality (Yacoub-Agha, et al,
Transplantation 2004). GI endoscopy, although critical to estab-
lishing early diagnosis and grading of AGVHD, poses additional
risks such as bleeding and perforation to already immunocompro-
mised patients. The objective of this study was to determine if upper
GI endoscopy (ED) with duodenum biopsy (Bx) adds diagnostic ac-
curacy to lowerGI ED and colon biopsy in pediatric alloSCT recip-
ients. Methods: We performed a retrospective review of pediatric
alloSCT recipients who underwent upper (UE) and lower (LE)
GI ED at Morgan Stanley Children’s Hospital-New York Presby-
terian between 2001 and 2005. Biopsies were evaluated by a gastro-
intestinal pathologist blinded to clinical data to correlate biopsy
sites with histological findings of GI AGVHD. To examine which
sites were more likely to be diagnostic of AGVHD, six pairwise
comparisons were made between different sites, using the McNe-
mar Test with Bonferroni correction so that p\ 0.008 (50.05/6)
represents statistical significance. Results: We evaluated 50 pa-
tients (age range 0.8 to 17.6 yr, mean 7.6 yr; M 27, F 23) 24 to
100 days post alloSCT suspected of AGVHD who underwent
both upper and lower GI ED. The number of Bx sites per patient
ranged from 4 to 10, median 7. For upper endoscopy, 48 patients
had both duodenal and stomach biopsies, the duodenum was
more likely to be positive than stomach, OR 3.7 (p 5 0.005). For
lower endoscopy cases, there were no significant differences in pro-
portion of positive biopsies between ascending and sigmoid, sig-
moid and transverse, or left versus right colon. However,
comparing LE to UE, left colon was significantly more likely to
be positive than duodenum, OR 12.0 (p 5 0.006). There were 12
cases where the left colon was positive and duodenum negative
and only 1 case where the reverse was true. Conclusions: Overall,duodenum and colon are most likely sites to be positive for GI
AGVHD. Left-sided colonoscopy and left colon biopsy are more
sensitive to detect AGVHD compared to upper endoscopy and gas-
tric and duodenal biopsies. Eliminating concomitant upper endos-
copy and biopsies if a lower endoscopy is performed could
potentially reduce morbidity in pediatric allograft recipients. How-
ever, if upper endoscopy is indicated, duodenal biopsies yield amore
accurate diagnosis than gastric biopsies.361
THE PHARMACODYNAMIC ANALYSIS BETWEEN CYCLOSPORINE A (CsA)
AND CYTOKINE PROFILES OF CD41 T LYMPHOCYTES FOR THE DEVEL-
OPMENT OF OPTIMIZED IMMUNOSUPPRESSIVE THERAPY WITH CsA
AFTER UNRELATED CORD BLOOD TRANSPLANTATION (CBT)
Tsukada, N.1, Ishige, M.2, Konuma, T.1, Kato, S.1, Kasahara, S.1,
Tomonari, A.1, Ooi, J.1, Tojo, A.1, Watanabe, N.2, Nakauchi, H.2,
Masuko, M.3, Furukawa, T.3, Aizawa, Y.3, Takahashi, S.1. 1 Institute
of Medical Science, University of Tokyo, Minato Ward, Tokyo, Japan;
2 Institute of Medical Science, University of Tokyo, Minato Ward, Tokyo,
Japan; 3Niigata University Medical and Dental Hospital, Niigata City,
Niigata, Japan.
Although unrelated cord blood transplantation (CBT) is increas-
ing in number, the optimized immunosuppressive therapy for pre-
vention of graft versus host disease (GVHD) has not been
established. Cyclosporine A (CsA) is the most common immuno-
suppressant used for GVHD prophylaxis and individualization
among types of stem cell source by using therapeutic drug monitor-
ing (TDM) is essential to optimize pharmacotherapy. Cord blood
lymphocytes are naı¨ve and most of CBT are carried out with a hu-
man leukocyte antigen (HLA)-mismatched combination especially
in adults. Our retrospective analysis showedCsA can be tapered ear-
lier for recipients of CBT than for those of BMT. To optimize CsA
administration in CBT, we analyzed proportion of IL-2 producing
cells among CD41T lymphocytes using multi-color flow cytomet-
ric analysis before and after CsA administration. We analyzed 55
peripheral blood samples from 6 allogeneic BMT recipients as con-
trols and 104 peripheral blood samples from 7 CBT recipients.
Cells were cultured in the presence of phorbol 12-myristate 13-ac-
etate, ionomycin, and monensin at 37C for 4 hrs and then stained
for surface markers and intracytoplasmic IL-2. Blood CsA levels
were simultaneouslymeasured.We found that the level of IL-2 pro-
duction in CD41 T lymphocytes was inversely proportional to
blood CsA levels for both BMT and CBT. IL-2 production in
CD41 T lymphocytes of cord blood recipients can be inhibited
by relatively lower CsA concentration compared with that of bone
marrow recipients. To our most interest, there was dramatic differ-
ence in required blood CsA level for inhibition of IL-2 production
by days after transplantation (e.g. before and after day45) in recipi-
ents of CBT, while there was no difference by days after transplan-
tation in recipients of BMT. This finding can explain why earlier
tapering of CsA is possible for cord blood recipients. Further anal-
ysis is needed to optimize blood CsA level on different days after
CBT for GVHD prophylaxis.362
INCIDENCE AND RISK FACTORS FOR CHRONIC GRAFT-VERSUS-HOST
DISEASE (cGVHD) AFTER CORD BLOOD TRANSPLANTATION (CBT)
Saliba, R.M.1, Couriel, D.2, Komanduri, K.1, Patah, P.3, Westin, J.1,
Giralt, S.1, Cooper, L.4, Petropoulos, D.4, Worth, L.4, Safdar, A.5,
Champlin, R.E.1, Shpall, E.J.1, de Lima, M.1. 1UTMDAnderson Can-
cer Center, Houston, TX; 2Tennesse Oncology, Nashville, TN; 3Hospital
Sirio Libanes, Sao Paulo, Brazil; 4UT MD Anderson Cancer Center,
Houston, TX; 5UT MD Anderson Cancer Center, Houston, TX.
Objective:To evaluate the impact of patient and transplant char-
acteristics on the incidence of cGVHD after CBT.Methods: Ret-
rospective study of all CBT performed at our institution between
1996 and 2007, excluding primary graft failure cases. 114 patients
were analyzed. All had high-risk hematologic malignancies; 59%
were in complete remission or chronic phase at transplantation.
Median age was 37 years (range 18–67) in the adult group (n 5
61) and 7 years (range 0.5–17) in the pediatric group (n 5 53).
